对于声称有效的阿尔茨海默病药物，质疑依然存在。 - Suppr

Suppr

超能文献

Doubts persist for claimed Alzheimer's drug.

作者信息

Servick Kelly

出版信息

Science. 2019 Dec 13;366(6471):1298. doi: 10.1126/science.366.6471.1298.

DOI:10.1126/science.366.6471.1298

PMID:31831649

Abstract

摘要

相似文献

Doubts persist for claimed Alzheimer's drug.

Science. 2019 Dec 13;366(6471):1298. doi: 10.1126/science.366.6471.1298.

Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.

N Engl J Med. 2021 Aug 26;385(9):771-774. doi: 10.1056/NEJMp2111320. Epub 2021 Jul 28.

Landmark Alzheimer's drug approval confounds research community.

Nature. 2021 Jun;594(7863):309-310. doi: 10.1038/d41586-021-01546-2.

Revisiting FDA Approval of Aducanumab.

N Engl J Med. 2021 Aug 26;385(9):769-771. doi: 10.1056/NEJMp2110468. Epub 2021 Jul 28.

Side effects loom over Alzheimer's drugs.

Science. 2023 Aug 4;381(6657):466-467. doi: 10.1126/science.adk0830. Epub 2023 Aug 3.

US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?

JAMA Neurol. 2021 Nov 1;78(11):1307-1308. doi: 10.1001/jamaneurol.2021.3126.

FDA approves third anti-amyloid antibody for Alzheimer disease.

Nat Rev Drug Discov. 2024 Aug;23(8):571. doi: 10.1038/d41573-024-00116-1.

A carte blanche approval in Alzheimer's.

Nat Biotechnol. 2021 Jul;39(7):781. doi: 10.1038/s41587-021-00995-4.

Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered.

JAMA. 2021 Aug 10;326(6):469-472. doi: 10.1001/jama.2021.11558.

Report on trial death stokes Alzheimer's drug fears.

Science. 2023 Apr 14;380(6641):122-123. doi: 10.1126/science.adi2242. Epub 2023 Apr 13.

引用本文的文献

Molecular Mechanism of Cyanidin-3--Glucoside Disassembling Aβ Fibril In Silico.

Nutrients. 2022 Dec 26;15(1):109. doi: 10.3390/nu15010109.

Machine Learning for Discovery of GSK3β Inhibitors.

ACS Omega. 2020 Oct 12;5(41):26551-26561. doi: 10.1021/acsomega.0c03302. eCollection 2020 Oct 20.

Heavy Tau Burden with Subtle Amyloid β Accumulation in the Cerebral Cortex and Cerebellum in a Case of Familial Alzheimer's Disease with APP Osaka Mutation.

Int J Mol Sci. 2020 Jun 22;21(12):4443. doi: 10.3390/ijms21124443.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Doubts persist for claimed Alzheimer's drug.

Science. 2019 Dec 13;366(6471):1298. doi: 10.1126/science.366.6471.1298.

Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.

N Engl J Med. 2021 Aug 26;385(9):771-774. doi: 10.1056/NEJMp2111320. Epub 2021 Jul 28.

Landmark Alzheimer's drug approval confounds research community.

Nature. 2021 Jun;594(7863):309-310. doi: 10.1038/d41586-021-01546-2.

Revisiting FDA Approval of Aducanumab.

N Engl J Med. 2021 Aug 26;385(9):769-771. doi: 10.1056/NEJMp2110468. Epub 2021 Jul 28.

Side effects loom over Alzheimer's drugs.

Science. 2023 Aug 4;381(6657):466-467. doi: 10.1126/science.adk0830. Epub 2023 Aug 3.

US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?

JAMA Neurol. 2021 Nov 1;78(11):1307-1308. doi: 10.1001/jamaneurol.2021.3126.

FDA approves third anti-amyloid antibody for Alzheimer disease.

Nat Rev Drug Discov. 2024 Aug;23(8):571. doi: 10.1038/d41573-024-00116-1.

A carte blanche approval in Alzheimer's.

Nat Biotechnol. 2021 Jul;39(7):781. doi: 10.1038/s41587-021-00995-4.

Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered.

JAMA. 2021 Aug 10;326(6):469-472. doi: 10.1001/jama.2021.11558.

Report on trial death stokes Alzheimer's drug fears.

Science. 2023 Apr 14;380(6641):122-123. doi: 10.1126/science.adi2242. Epub 2023 Apr 13.

引用本文的文献

Molecular Mechanism of Cyanidin-3--Glucoside Disassembling Aβ Fibril In Silico.

Nutrients. 2022 Dec 26;15(1):109. doi: 10.3390/nu15010109.

Machine Learning for Discovery of GSK3β Inhibitors.

ACS Omega. 2020 Oct 12;5(41):26551-26561. doi: 10.1021/acsomega.0c03302. eCollection 2020 Oct 20.

Heavy Tau Burden with Subtle Amyloid β Accumulation in the Cerebral Cortex and Cerebellum in a Case of Familial Alzheimer's Disease with APP Osaka Mutation.

Int J Mol Sci. 2020 Jun 22;21(12):4443. doi: 10.3390/ijms21124443.